TipRanks
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315)
:2315
Hong Kong Market
2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
RESEARCH TOOLSreports
Want to see HK:2315 full AI Analyst Report?

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) Ratios

1 Followers

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Ratios

HK:2315's free cash flow for Q2 2026 was ¥0.79. For the 2026 fiscal year, HK:2315's free cash flow was decreased by ¥ and operating cash flow was ¥0.29. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
 3.30 2.31 1.53 1.25 1.52
Quick Ratio
 2.86 2.12 1.33 1.23 1.36
Cash Ratio
 1.86 1.68 0.71 0.69 1.00
Solvency Ratio
 0.43 0.22 0.13 -0.12 -0.28
Operating Cash Flow Ratio
 0.82 0.40 0.39 -0.13 -0.50
Short-Term Operating Cash Flow Coverage
 1.77 1.89 1.01 -0.43 -2.39
Net Current Asset Value
¥ 428.76M¥ 603.86M¥ -760.18M¥ -935.92M¥ -729.72M
Leverage Ratios
Debt-to-Assets Ratio
 0.24 0.16 0.24 0.22 0.15
Debt-to-Equity Ratio
 0.36 0.27 0.68 0.69 0.36
Debt-to-Capital Ratio
 0.26 0.21 0.41 0.41 0.27
Long-Term Debt-to-Capital Ratio
 0.09 0.08 0.19 0.18 0.04
Financial Leverage Ratio
 1.50 1.71 2.90 3.12 2.44
Debt Service Coverage Ratio
 1.88 1.52 0.98 -0.36 -2.55
Interest Coverage Ratio
 6.05 3.92 1.79 -2.71 -9.45
Debt to Market Cap
 0.02 0.03 0.13 0.09 0.02
Interest Debt Per Share
 2.12 1.64 1.66 1.62 1.20
Net Debt to EBITDA
 -0.10 -2.33 0.62 -1.48 0.40
Profitability Margins
Gross Profit Margin
77.06%75.83%77.67%70.59%73.38%
EBIT Margin
25.17%18.79%13.73%-39.10%-113.25%
EBITDA Margin
34.41%30.42%30.99%-13.65%-87.26%
Operating Profit Margin
25.96%20.21%16.76%-37.70%-99.36%
Pretax Profit Margin
22.19%13.64%4.38%-53.03%-112.64%
Net Profit Margin
21.54%12.56%3.42%-53.42%-112.79%
Continuous Operations Profit Margin
21.54%12.56%3.42%-53.42%-112.79%
Net Income Per EBT
97.09%92.11%78.11%100.74%100.13%
EBT Per EBIT
85.46%67.49%26.12%140.65%113.37%
Return on Assets (ROA)
10.06%4.65%1.39%-15.63%-21.51%
Return on Equity (ROE)
15.94%7.96%4.02%-48.73%-52.53%
Return on Capital Employed (ROCE)
14.04%9.97%8.74%-14.44%-24.18%
Return on Invested Capital (ROIC)
12.71%8.49%6.09%-13.03%-22.43%
Return on Tangible Assets
10.09%4.67%1.40%-15.82%-21.74%
Earnings Yield
1.73%1.37%1.06%-9.42%-6.77%
Efficiency Ratios
Receivables Turnover
 5.43 4.39 4.18 5.01 4.96
Payables Turnover
 4.25 2.45 1.90 1.20 0.97
Inventory Turnover
 1.78 1.91 2.11 21.31 1.49
Fixed Asset Turnover
 0.97 1.01 0.73 0.49 0.33
Asset Turnover
 0.47 0.37 0.41 0.29 0.19
Working Capital Turnover Ratio
 1.44 1.84 4.59 3.13 1.44
Cash Conversion Cycle
 186.49 125.68 67.39 -213.36 -57.58
Days of Sales Outstanding
 67.22 83.05 87.26 72.82 73.62
Days of Inventory Outstanding
 205.06 191.42 172.65 17.13 244.23
Days of Payables Outstanding
 85.79 148.79 192.52 303.31 375.42
Operating Cycle
 272.28 274.47 259.91 89.95 317.85
Cash Flow Ratios
Operating Cash Flow Per Share
 0.93 0.93 0.53 -0.19 -0.77
Free Cash Flow Per Share
 0.31 0.71 0.44 -0.51 -1.39
CapEx Per Share
 0.62 0.22 0.09 0.32 0.61
Free Cash Flow to Operating Cash Flow
 0.34 0.76 0.82 2.65 1.79
Dividend Paid and CapEx Coverage Ratio
 1.50 4.22 5.69 -0.61 -1.26
Capital Expenditure Coverage Ratio
 1.50 4.22 5.69 -0.61 -1.26
Operating Cash Flow Coverage Ratio
 0.47 0.63 0.37 -0.14 -0.73
Operating Cash Flow to Sales Ratio
 0.24 0.27 0.22 -0.11 -0.57
Free Cash Flow Yield
0.71%2.23%5.48%-5.00%-6.12%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 56.08 73.74 94.73 -10.61 -14.77
Price-to-Sales (P/S) Ratio
 11.37 9.20 3.24 5.67 16.66
Price-to-Book (P/B) Ratio
 8.73 5.83 3.81 5.17 7.76
Price-to-Free Cash Flow (P/FCF) Ratio
 140.34 44.91 18.25 -19.99 -16.35
Price-to-Operating Cash Flow Ratio
 51.43 34.26 15.04 -53.02 -29.33
Price-to-Earnings Growth (PEG) Ratio
 0.37 0.18 -0.87 0.28 -1.36
Enterprise Value Multiple
 32.94 27.91 11.08 -43.00 -18.69
Enterprise Value
 19.27B 11.71B 3.37B 4.21B 8.71B
EV to EBITDA
 32.94 27.91 11.08 -43.00 -18.69
EV to Sales
 11.33 8.49 3.43 5.87 16.31
EV to Free Cash Flow
 139.90 41.45 19.33 -20.70 -16.01
EV to Operating Cash Flow
 46.88 31.62 15.94 -54.91 -28.71
Tangible Book Value Per Share
 5.44 5.41 2.06 1.91 2.85
Shareholders’ Equity Per Share
 5.46 5.44 2.10 1.97 2.92
Tax and Other Ratios
Effective Tax Rate
 0.03 0.08 0.22 >-0.01 >-0.01
Revenue Per Share
 3.83 3.45 2.46 1.80 1.36
Net Income Per Share
 0.83 0.43 0.08 -0.96 -1.53
Tax Burden
 0.97 0.92 0.78 1.01 1.00
Interest Burden
 0.88 0.73 0.32 1.36 0.99
Research & Development to Revenue
 0.29 0.32 0.33 0.66 1.31
SG&A to Revenue
 0.26 0.29 0.32 0.40 0.49
Stock-Based Compensation to Revenue
 <0.01 0.03 0.02 0.04 0.03
Income Quality
 1.09 1.97 4.92 0.20 0.50
Currency in CNY